Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
NCT05686408 is registered in ClinicalTrials.gov with Tonix Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
- Lead sponsor
- Tonix Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 2, 2023
- Completion date
- September 29, 2023
- Enrollment
- 132 (actual)
- Sites
- 27
Conditions
As the registry lists them; a condition with its own page is linked.
depression, depression severe, depressive disorder, depressive disorder, major, depressive episode, depressive symptoms